Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Mostrar outras versões (1)

Introduction - Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance. Underlying mechanisms have been largely attributed to genetic changes, but a substantial proportion of resistance observations remain une...

ver descrição completa

Detalhes bibliográficos
Principais autores: Claas, Allison Mary, Atta, Lyla H., Gordonov, Simon, Meyer, Aaron Samuel, Lauffenburger, Douglas A
Outros Autores: Massachusetts Institute of Technology. Department of Biological Engineering
Formato: Artigo
Idioma:English
Publicado em: Springer US 2018
Acesso em linha:http://hdl.handle.net/1721.1/117218
https://orcid.org/0000-0003-1224-8153
https://orcid.org/0000-0001-6284-2711
https://orcid.org/0000-0002-0050-989X

Internet

http://hdl.handle.net/1721.1/117218
https://orcid.org/0000-0003-1224-8153
https://orcid.org/0000-0001-6284-2711
https://orcid.org/0000-0002-0050-989X

Registros relacionados